Maribavir: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Maribavir. Educational only — not medical advice.
Labeled uses
LIVTENCITY® is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet [see Use in Specific Populations (8.4) and Clinical Studies (14) ] .
Source: FDA labeling via NIH DailyMed (set c94fc2c5…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.